QUANTITY LIMIT CRITERIA

DRUG CLASS	**ANTIVIRAL FOR THE TREATMENT OF COVID-19**
BRAND NAME (generic)	**LAGEVRIO (molnupiravir)**

Status: CVS Caremark® Criteria
Type: Quantity Limit

POLICY

USES
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product Lagevrio for treatment of adults with mild-to-moderate coronavirus disease 2019 (COVID-19):

- who are at high risk for progression to severe COVID-19, including hospitalization or death.
- for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.

Limitations of Use

- Lagevrio is not authorized for use in patients who are less than 18 years of age.
- Lagevrio is not authorized for initiation of treatment in patients hospitalized due to COVID-19. Benefit of treatment with Lagevrio has not been observed in subjects when treatment was initiated after hospitalization due to COVID-19.
- Lagevrio is not authorized for use for longer than 5 consecutive days.
- Lagevrio is not authorized for pre-exposure or post-exposure prophylaxis for prevention of COVID-19.

INITIAL LIMIT QUANTITY

Drug	**Limit***
Lagevrio (molnupiravir) 200 mg capsule	40 capsules / 30 days

**** This drug is for short-term acute use.***

REFERENCES

1. Lagevrio [Emergency Use Authorization Fact Sheet for Healthcare Providers]. Rahway, NJ: Merck Sharp & Dhome LLC; October 2023.
2. Lexicomp Online, Lexi-Drugs Online. Waltham, MA: UpToDate, Inc.; 2023. https://online.lexi.com. Accessed October 26, 2023.
3. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 10/26/2023).